Researchers are turning to PODS sustained release formulation to easily generate stable chemokine gradients in a variety of situations
There is no single international standard for what qualifies as a rare disease. In the UE, it is a disease that affect fewer than 1 in 2000 people.
Since emerging in the last 20 years, expectations for exosomes have developed into hype in some areas. What is their real potential?
As new therapies emerge, charitable funding has become crucial, accelerating early research, supporting clinical trials, and offering renewed hope for affected children and families.
Critical gaps between experimental models and clinical reality are the reason why clinical trials of promising drugs often fail. Closing those gaps can save huge amounts of money lost to failed trials. The right scaffold is critical to model accuracy
When researchers at the University of Helsinki set out to understand how the mechanical properties of breast tumors affect immune cell behavior, they needed a culture system that could faithfully recreate different tissue environments. Their choice of PeptiGel as a 3D culture matrix proved instrumental in uncovering a surprising mechanism of immune suppression in breast cancer.
Molecular structure such as small molecules and proteins are typically measure in Daltons. Whereas larger structures are measure in grams. Here we explain why, and how these units they relate to each other.
Affinity-based biosensors use antibodies or aptamers to detect cytokines but suffer from slow dissociation kinetics (half-lives up to ~20 hours). Addressing this kinetic bottleneck enables real-time monitoring of concentration.
Providing building blocks for controlled protein release, the inspired use of PODS is enabling research breakthroughs across biomedical science.
Last week, a Nobel prize was awarded for the discovery of T-Reg cells. When and how many immune cells have been identified and are there likely more lurking in the shadows?
